G

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Senior Manager - Data/AI Solution Architect

Full-Time
$146.2k - $219.1k+ Discretionary annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's
Foster City, CA, USA+1 moreMore locations: Raleigh, NC, USA
HybridHybrid-eligible; onsite work is based in Foster City or Raleigh.
Software EngineeringAI Application Engineering
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A Bachelor's degree and eight years of experience, or a Master's degree and six years of experience.
  • Five or more years of experience in AI/ML engineering, including hands-on work building LLM/generative-AI applications using fine-tuning, retrieval-augmented generation, and prompt engineering.
  • Strong programming skills in Python and modern machine learning frameworks.
  • Experience designing knowledge bases and retrieval systems over large structured and unstructured sources.
  • Experience with AWS cloud AI platforms and MLOps tooling.
  • Solid data engineering fundamentals, including pipelines, data modeling, and large-scale processing.
  • Experience delivering a portfolio of solutions across multiple business functions, including leading delivery through engineering teams and external partners.
  • Experience in pharmaceutical, biotech, life sciences, or other highly regulated industries.
  • Familiarity with technology policies, compliance, and governance workflows in a regulated enterprise environment.
  • Experience with enterprise context building and automation.
  • Experience handling confidential and sensitive enterprise data, including HR and Legal data, with appropriate privacy controls.
  • Experience with responsible AI, model governance, and validation in regulated environments.
Responsibilities
  • Partner with business process leads across HR, Compliance, and Legal to assess needs, translate them into practical AI solution designs, and serve as the technical lead across solutions.
  • Build, fine-tune, and evaluate AI/LLM models grounded in policy, procedural, and regulatory requirements and adaptable to company-specific content, internal materials, and approved templates.
  • Design and maintain retrieval-augmented knowledge bases incorporating authoritative external guidance, corporate policy libraries, compliance frameworks and codes of conduct, and company-specific documentation.
  • Develop reusable capabilities for document review, summarization, consistency and policy-alignment checking, citation accuracy, and risk flagging, with traceable citations back to source content.
  • Engineer secure, scalable ingestion and processing pipelines for diverse content types across enterprise support functions, including policy and procedure documents, employee-facing communications, training and enablement materials, internal narratives, external publications, and structured business records.
  • Direct execution through engineers, vendor partners, and shared platform resources; set technical direction, review designs, ensure quality, and drive solutions to production at a scale beyond individual delivery.
  • Establish evaluation frameworks, accuracy benchmarks, guardrails, and human-in-the-loop validation to ensure trustworthy, defensible, and auditable outputs.
  • Bridge business stakeholders and AI delivery by converting functional review and knowledge-work needs into trusted, auditable solutions that reduce cycle time and organizational risk; drive adoption, enablement, and change management.
  • Ensure solutions meet data privacy, confidentiality, security, and responsible-AI standards, with role-based access appropriate to sensitive enterprise content.
  • Implement model deployment, monitoring, versioning, and continuous improvement practices, and establish reusable architecture standards and delivery patterns across the portfolio.

About the company

Gilead Sciences is a biopharmaceutical company that discovers, develops and sells medicines for HIV, viral hepatitis and other liver diseases, cancer and inflammatory conditions. Its HIV business covers both treatment, led by the once-daily pill Biktarvy, and prevention, including Descovy and Yeztugo, a lenacapavir injection given twice a year. In cancer, its Kite unit makes CAR T-cell therapies from patients' own immune cells, and Trodelvy is an antibody-drug conjugate for breast cancer. Gilead earns revenue by selling its drugs to wholesalers, specialty pharmacies, hospitals and governments worldwide after regulatory approval. The company was founded in 1987 and is headquartered in Foster City, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead is expanding at headquarters: it broke ground on a Foster City biologics plant in August 2026.
  • Its top seller has a long runway: generic deals keep US copies of Biktarvy off shelves until April 2036.
  • Acquisitions add teams to join: Gilead bought German drug developer Tubulis for about $3.2 billion in May 2026.

What critics are saying

  • Sales lean on one disease: HIV drugs made $5.7 billion of Gilead's $7.8 billion revenue in Q2 2026.
  • Medicare will set Biktarvy's price: officials picked it in January 2026 for negotiated prices starting in 2028.
  • Expect cuts: Gilead reported 108 Redwood City and 51 San Mateo layoffs taking effect by June 2026.

What makes Gilead Sciences unique

  • Gilead sells a twice-a-year HIV prevention shot: Yeztugo replaces daily pills with two injections a year.
  • Gilead now fully owns a myeloma cell therapy: it bought partner Arcellx for about $7.8 billion in April 2026.
  • Gilead makes cell therapies in-house: Kite runs its own CAR T plants in California, Maryland and Amsterdam.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Paid family time off and paid parental time off
  • Generous 401(k) contribution matching
  • Comprehensive medical plans that cover both physical and mental healthcare
  • Global Wellbeing Reimbursement
  • Time Off
  • Global Volunteer Day
  • Giving Together Program
  • Employee Support Programs
  • Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
TradingView
Oct 16th, 2026
Stocktwits biotech dealmaker: Gilead, AstraZeneca and Roche chase pipeline expansion over buyouts.

Stocktwits biotech dealmaker: Gilead, AstraZeneca and Roche chase pipeline expansion over buyouts. Key points: * Gilead Sciences partnered with Vir Biotechnology on Wednesday to discover and develop three drugs aimed at solid tumors. * AstraZeneca signed an up-to-$1.5 billion AI collaboration with insitro for MASH and cardiomyopathies. * Roche licensed Rona's drug candidate, and Zealand Pharma teamed with Generate on AI-designed proteins for differentiated obesity approaches. Large pharmaceutical companies including Gilead Sciences, Roche and AstraZeneca spent this week securing access to discovery technologies and experimental candidates that address clear biological gaps, instead of large-scale acquisitions of rival firms or approved products. Obesity and cancer remained the clear focal points, with several of the week's biggest partnerships aimed at differentiated weight-loss mechanisms or new solid-tumor approaches. Gilead Partners With Vir For New Cancer Drug Candidates Gilead Sciences (GILD) partnered with Vir Biotechnology (VIR) on Wednesday to discover and develop three drugs aimed at solid tumors. Vir will handle early discovery, design, and optimization using its AI-enabled protein engineering tools and PRO-XTEN masking technology. Gilead receives exclusive rights to nominate candidates and will lead subsequent development, manufacturing, and commercialization. Vir is eligible for $90 million upfront - $65 million in cash plus a $25 million equity investment at a premium - plus up to $45 million in near-term preclinical milestones and as much as $1.74 billion in later development, regulatory, and commercial payments, along with tiered royalties. The agreement marks Vir's second major partnership around its masking platform this year after a previous deal with Astellas and adds to Gilead's attempts to advance its cancer offerings besides its blockbuster drug Trodelvy. AstraZeneca Taps Insitro's AI Platform AstraZeneca (AZN) signed a worldwide exclusive research collaboration with privately held AI therapeutics company insitro focused on metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Insitro will apply its Virtual Human platform, which combines human and cellular data with AI, to identify causal disease biology and advance AstraZeneca-nominated targets through discovery to the development-candidate stage. AstraZeneca will lead clinical development, regulatory work, and commercialization. Insitro will receive $40 million upfront and is eligible for up to approximately $1.46 billion in discovery, development, and commercial milestones, plus single-digit royalties on potential sales. Roche, Zealand Pharma Add Differentiated Obesity Approaches Roche secured exclusive worldwide rights to Rona Therapeutics' investigational drug candidate which targets a protein predominantly expressed in fat tissues. The drug candidate is designed to selectively reduce visceral and ectopic fat while preserving lean mass - an attractive complement to currently popular obesity drug classes like GLP-1. Rona is eligible for up to $100 million in upfront and near-term payments, up to $1.06 billion in additional milestones, and tiered royalties. Separately, Zealand Pharma entered a collaboration with Generate Biomedicines (GENB) to design multispecific protein therapeutics for obesity and other metabolic diseases using Generate's generative AI platform. Generate will lead research through lead-candidate selection for two initial programs, with an option for a third; Zealand will handle clinical development, regulatory submissions, and commercialization. Generate receives $30 million upfront, up to $35 million in early preclinical milestones, and nearly $1.2 billion in total potential milestones, plus royalties. Pfizer, Galderma Make Platform And Commercial Moves Pfizer (PFE) partnered with privately-held Enodia Therapeutics on a research collaboration and license for compounds intended to block disease-driving proteins at the point of synthesis. The potential value exceeds $500 million, including an upfront payment, milestones, and royalties; Enodia will run discovery against multiple targets while Pfizer takes over later development and commercialization. How Did Retail Traders React? On Stocktwits, retail sentiment around SPDR S&P Biotech ETF (XBI) fell from bullish to neutral territory over the past 24 hours, while message volume stayed at normal levels. XBI has fallen 4% over the past week as part of a broader biotech pullback that began after its mid-August peak near $170, but it is up 22.5% year-to-date.

PharmaVoice
Oct 15th, 2026
Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers.

Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers. Oct 15, 2026, 1:30 PM Translate article text Choose a language and wait for the translated text. This deal sees Gilead double down on TCEs, following its first bet on the modality through its buyout of autoimmune-focused Ouro Medicines.

MarketScreener
Oct 14th, 2026
Vir Biotechnology shares jump on Gilead cancer collaboration.

Vir Biotechnology shares jump on Gilead cancer collaboration. Published on 10/14/2026 at 10:00 am EDT - Modified on 10/14/2026 at 10:01 am EDT By Adriano Marchese Vir Biotechnology shares jumped Wednesday morning after the company said it signed an agreement with Gilead Sciences to discover and develop next-generation t-cell engagers for solid tumors. Shares traded 8.2% at $11.48 ahead of the morning bell. The clinical-stage biopharmaceutical company has signed a collaboration and license agreement with Gilead to discover and engineer three novel dual-masked T-cell engager development candidates aimed at targeting solid tumor-associated antigens. T-cell engagers, or TCEs, are powerful anti-tumor agents designed to direct the immune system, specifically T-cells, to destroy cancer cells. TCEs have become an important treatment option for blood cancers, but their usage in solid tumors has been limited due to toxicity. Gilead will have an exclusive license to nominate and advance candidates developed under the collaboration and will be responsible for development, manufacturing and commercialization activities. As part of the deal, Vir will be in line to receive a total of $135 million in payments, made up of a $65 million cash portion and a $25 million equity investment at a 30% premium, as well as up to $45 million in potential near-term preclinical milestones. Vir added that it has the potential to receive up to $1.74 billion in further development, regulatory and commercial milestones, along with tiered high single-digit to low double-digit royalties on net sales. Write to Adriano Marchese at [email protected] (END) Dow Jones Newswires 10-14-26 0959ET (C) Dow Jones - 2026

MarketScreener
Oct 14th, 2026
Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal.

Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal. Published on 10/14/2026 at 09:22 am EDT or by email Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%). Mean consensus Number of Analysts Last Close Price 147.92 USD Average target price 159.62 USD Spread / Average Target

Hip-Hop Wired
Oct 8th, 2026
Raheem DeVaughn on R&B and Black mental health.

Raheem DeVaughn on R&B and Black mental health. Published on October 8, 2026 Raheem DeVaughn talks ownership, R&B, and healing on The Morning Hustle. R&B mainstay Raheem DeVaughn stopped by The Morning Hustle for a conversation that spanned business, music, and community. The DMV favorite opened up about his new project, Quiet Storm Lover Tome Un, and his decision to re-record his 20th-anniversary album, The Love Experience. For DeVaughn, the move is about ownership. Re-recording old work creates a new master, and he wants to lead by example for independent and legacy artists chasing control of their catalogs. He also shared his love for where R&B stands today, praising fresh work from Erykah Badu and Jill Scott. DeVaughn makes music with intention, refusing to chase trends for quick money. "Music is only old to someone who hasn't heard it yet," he said, describing his focus on timeless songs that keep fans dancing for hours at deep-catalog shows. Beyond the mic, DeVaughn stays active in the community. Through his Love Life Foundation and a partnership with Gilead Sciences on the "Care for the Culture" initiative, he urges people to get tested and know their status. He also spoke candidly about mental health, encouraging Black men to seek therapy. Losing his father, he shared, pushed him into the work that revealed his own strength. Looking ahead, DeVaughn teased a City Winery tour bringing his classics to life live for fans. Stories from our partners. OkayAfrica